Kling Douglas F
SEC CIK 1699022 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| NAMS | NewAmsterdam Pharma Co N.V. | COO | 95.0K | — | $4.03M | 19 | 2025-01-07 | 2025-07-15 |
Most active insiders at NAMS, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Davidson Michael H. | CEO, Dir | $226.5K | $25.33M |
| 2 | Kooij Louise Frederika | CAO | — | $16.75M |
| 3 | Kastelein Johannes Jacob Pieter | CSO, Dir | — | $14.26M |
| 4 | Somaiya Mayur Ian | CFO | — | $3.43M |
| 5 | LANGE LOUIS G | Dir | — | $2.19M |
| 6 | Smither John W | Dir | — | $40.5K |
| 7 | Gunning Robert William | VP, Ctrl | — | — |
| 8 | van der Kamp Hilde Johanna | Dir | — | — |
| 9 | McKenna Mark C. | Dir | — | — |
| 10 | Gulfo Adele M. | Dir | — | — |
Kling Douglas F made no open-market trades at NAMS in the last 12 months.
Transactions 19
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2025-07-17 | 2025-07-15+ | NAMS | NewAmsterdam Pharma Co N.V. | Kling Douglas F | COO | M - OptEx | $10.90 | +98.6K | 95.0K | New | +$1.07M |
| DMT | 2025-07-17 | 2025-07-15+ | NAMS | NewAmsterdam Pharma Co N.V. | Kling Douglas F | COO | S - Sale+OE | $21.26 | -98.6K | 44.0K | -69% | -$2.10M |
| DMT | 2025-06-18 | 2025-06-16 | NAMS | NewAmsterdam Pharma Co N.V. | Kling Douglas F | COO | M - OptEx | $10.20 | +100.0K | 122.1K | +452% | +$1.02M |
| DMT | 2025-06-18 | 2025-06-16 | NAMS | NewAmsterdam Pharma Co N.V. | Kling Douglas F | COO | S - Sale+OE | $19.29 | -100.0K | 62.1K | -62% | -$1.93M |
| DT | 2025-05-19 | 2025-05-15 | NAMS | NewAmsterdam Pharma Co N.V. | Kling Douglas F | COO | M - OptEx | $10.00 | +100.0K | 144.0K | +227% | +$1.00M |
| DT | 2025-05-19 | 2025-05-15 | NAMS | NewAmsterdam Pharma Co N.V. | Kling Douglas F | COO | S - Sale+OE | — | -100.0K | 44.0K | -69% | — |
| DT | 2025-04-17 | 2025-04-15 | NAMS | NewAmsterdam Pharma Co N.V. | Kling Douglas F | COO | M - OptEx | $10.00 | +100.0K | 144.0K | +227% | +$1.00M |
| DMT | 2025-04-17 | 2025-04-15 | NAMS | NewAmsterdam Pharma Co N.V. | Kling Douglas F | COO | S - Sale+OE | — | -100.0K | 44.0K | -69% | — |
| D | 2025-03-28 | 2025-03-26 | NAMS | NewAmsterdam Pharma Co N.V. | Kling Douglas F | COO | S - Sale+OE | — | -16.5K | 44.0K | -27% | — |
| D | 2025-03-28 | 2025-03-26 | NAMS | NewAmsterdam Pharma Co N.V. | Kling Douglas F | COO | M - OptEx | $0.00 | +16.5K | 60.5K | +38% | $0 |
| DMT | 2025-03-19 | 2025-03-17 | NAMS | NewAmsterdam Pharma Co N.V. | Kling Douglas F | COO | M - OptEx | $10.00 | +100.0K | 132.1K | +311% | +$1.00M |
| DT | 2025-03-19 | 2025-03-17 | NAMS | NewAmsterdam Pharma Co N.V. | Kling Douglas F | COO | S - Sale+OE | — | -100.0K | 44.0K | -69% | — |
| DMT | 2025-02-20 | 2025-02-18+ | NAMS | NewAmsterdam Pharma Co N.V. | Kling Douglas F | COO | M - OptEx | — | +100.0K | 53.2K | New | — |
| DMT | 2025-02-20 | 2025-02-18+ | NAMS | NewAmsterdam Pharma Co N.V. | Kling Douglas F | COO | S - Sale+OE | — | -100.0K | 44.0K | -69% | — |
| DMT | 2025-01-31 | 2025-01-29+ | NAMS | NewAmsterdam Pharma Co N.V. | Kling Douglas F | COO | M - OptEx | — | +70.4K | 100.9K | +232% | — |
| DMT | 2025-01-31 | 2025-01-29+ | NAMS | NewAmsterdam Pharma Co N.V. | Kling Douglas F | COO | S - Sale+OE | — | -70.4K | 44.0K | -62% | — |
| DMT | 2025-01-29 | 2025-01-27+ | NAMS | NewAmsterdam Pharma Co N.V. | Kling Douglas F | COO | S - Sale+OE | — | -129.6K | 49.1K | -72% | — |
| DMT | 2025-01-29 | 2025-01-27+ | NAMS | NewAmsterdam Pharma Co N.V. | Kling Douglas F | COO | M - OptEx | — | +129.6K | 69.4K | New | — |
| 2025-01-07 | 2025-01-07 | NAMS | NewAmsterdam Pharma Co N.V. | Kling Douglas F | COO | A - Grant | — | +44.0K | 44.0K | New | — |
Purchase Sale Sale after option exercise All abbreviations